Navigation Links
AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
Date:8/9/2012

REDWOOD CITY, Calif., Aug. 9, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and six months ended June 30, 2012 and provided a development update.

Net loss for the second quarter of 2012 was $7.2 million, or $0.35 per share, compared with a net loss of $4.8 million, or $0.25 per share, for the second quarter of 2011.  Common shares used in calculating basic and diluted earnings per share were 20,627,244 for the second quarter of 2012 compared to 19,374,909 common shares for the second quarter of 2011.

During the second quarter of 2012, AcelRx recognized revenue of $224,000 resulting from reimbursement for work completed under a research grant from the U.S. Army Medical Research and Material Command, or USAMRMC, for development of its ARX-04 product candidate, a Sufentanil NanoTab® for the treatment of moderate-to-severe acute pain. 

Research and development expenses for the quarter ended June 30, 2012 totaled $5.4 million, compared with $3.0 million for the quarter ended June 30, 2011.  The increase was primarily due to expenditures required to conduct two Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain. 

General and administrative expenses were $1.8 million for the quarter ended June 30, 2012, compared with $1.6 million for the quarter ended June 30, 2011.  The increase of $0.2 million resulted primarily from expenses associated with commercial market research and patent prosecution efforts.

For the six months ended June 30, 2012, AcelRx reported a net loss of $14.3 million, or $0.71 per sha
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
2. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
3. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
4. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
6. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
7. AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
8. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
9. Sales Force Effectiveness in Pharmaceuticals - Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency
10. Isis Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
11. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
(Date:8/28/2015)... 28, 2015  IP Shakti, LLC, today announced that it ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... new corporate identity signifies our transformation into a company focused ... platform for patent claim validity." ... proprietary AIA Shield™ platform, the Company commenced a corporate re-branding ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... RATON, Fla., Sept. 15 Watermark Medical , ... the sleep-disordered breathing market, has expanded the market reach ... strategic alliances with three leading sleep solution providers in ... SleepQuest , a national provider of comprehensive sleep apnea ...
... Sept. 15 ViroPharma Incorporated (Nasdaq: VPHM ... Phase 1 study of VP20621 (non-toxigenic Clostridium difficile ... Clostridium difficile infections (CDI), a common and dangerous ... of antibiotic medications.  VP20621 contains the spores of a ...
Cached Medicine Technology:Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 2Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 3Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 4ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 2ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 3ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 4ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 5ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 6
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business ... veterans leading in business. Mr. Troy Mizell, Chairman of the Board at ... Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, through their ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics throughout Southern ... sea diving. The act of recreational diving exposes the body to extreme ... is vital that all recreational and professional divers undergo regular comprehensive scuba physicals. ...
(Date:8/28/2015)... ... August 28, 2015 , ... United Benefit Advisors ... TJS Insurance Group as its newest Partner Firm. Founded in 1924 and headquartered ... them focused on their goals. Within the past 10 years, TJS Insurance Group ...
(Date:8/28/2015)... Abilene, Texas (PRWEB) , ... August 28, 2015 , ... ... penned a new publication and pleads for swift actions to be taken in ... of unnatural disasters. , Yisrayl says scientists have yet to understand fully the ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Healthpointe Now Offering Scuba Physicals 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2
... PICK: Connexins: providing protection to cells destroyed in type ... lifelong disease characterized by high levels of sugar (glucose) ... immune system attacking and destroying the cells in their ... glucose levels. Surprisingly, little is known about the mechanisms ...
... Goodwin HealthDay Reporter , SUNDAY, Nov. 6 ... fresheners may evoke the holiday season for some. For ... runny, itchy noses and sneezing to asthma attacks. ... risen, so have complaints from their patients about reactions ...
... for the first time, they show significant decreases in crime, ... Researchers assessed more than 200 at-risk boys annually from ... crime, tobacco, alcohol, and marijuana use changed over time. While ... behavior, they had not isolated the additional effects of fatherhood. ...
... cells know what cell types to become? Why do cells ... develop into cancer cells? These are some of the questions ... research has a very strong position internationally and one of ... of Copenhagen. She has just received an ERC Starting Grant ...
... School of Medicine is honored to announce gifts to ... Research Foundation Professorship in Integrative Oncology. This professorship will ... as national leaders in teaching, research, and patient care ... gifts from The Parker Foundation and Helen Moss Cancer ...
... published research shows that more patients with end-stage ... hemodialysis as their initial kidney replacement therapy over ... the study now available in Arthritis Care ... College of Rheumatology (ACR), also found that African ...
Cached Medicine News:Health News:JCI online early table of contents: Nov. 7, 2011 2Health News:JCI online early table of contents: Nov. 7, 2011 3Health News:JCI online early table of contents: Nov. 7, 2011 4Health News:JCI online early table of contents: Nov. 7, 2011 5Health News:JCI online early table of contents: Nov. 7, 2011 6Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 2Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 3Health News:Fatherhood can help change a man's bad habits 2Health News:Research in cellular memory 2Health News:Pioneering professorship will teach innovative, patient-centered approach to cancer 2Health News:Pioneering professorship will teach innovative, patient-centered approach to cancer 3Health News:Most lupus nephritis patients with end-stage renal disease opt for hemodialysis therapy 2
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... The Newmarket Laboratories RPR kits ... mixture of lipid antigens, which will ... serum or plasma. The particles are ... to eliminate non - specific reactions. ...
... a quality assurance reagent in assays detecting ... (TOXO IgG and TOXO IgM), IgG and ... and rubella IgM), IgG and IgM antibodies ... and IgG antibodies to herpes simplex virus ...
... The Diamedix Immunosimplicity (Is) Rubella ... procedure,intended for the qualitative and quantitative ... test can be performed either manually ... Automated EIA Processor. The results are ...
Medicine Products: